Efficacy of an insulin-like growth factor-interleukin-3 fusion protein in reversing the hematopoietic toxicity associated with azidothymidine in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 449-454

  Difalco, Marcos R ^b   Dufresne, Line ^b   Congote, Luis Fernando ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOMBYXIN; HEMOGLOBIN; HYBRID PROTEIN; HYBRID PROTEIN 406; INTERLEUKIN 3; SOMATOMEDIN; SOMATOMEDIN INTERLEUKIN 3 FUSION PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO TERMINAL SEQUENCE; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW; COLONY FORMING CELL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROID CELL; HEMATOPOIETIC CELL; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

ANIMALS; BACULOVIRIDAE; BLOOD GLUCOSE; BODY WEIGHT; ERYTHROPOIESIS; HEMATOPOIESIS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INTERLEUKIN-3; LEUKOCYTE COUNT; MICE; MICE, INBRED C57BL; NEUROPEPTIDES; RECOMBINANT FUSION PROTEINS; ZIDOVUDINE;

EID: 0031910267     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bastion Y, Campos L, Roubi N, Bienvenu J, Felman P, Dumontet C and Coiffier B (1995) IL-3 increases marrow and peripheral erythroid precursors in chronic pure cell aplasia presenting in childhood. Br J Haematol 89:413-416.
2. Clark SC and Kamen R (1987) The human hematopoietic colony-stimulating factors. Science 236:1229-1237.
3. Congote LF and Li Q (1994) Accurate processing and secretion in the baculovirus expression system of an erythroid cell stimulating factor consisting of a chimera of IGF II and an insect insulin-like peptide. Biochem J 299:101-107.
4. Crump M, Couture F, Kovacs M, Saragosa R, Mccrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L and Keating A (1993) Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 21:405-410.
5. Difalco MR and Congote LF (1997) Preparation of a recombinant chimera of insulin-like growth factor II and interleukin 3 with high proliferative potency for hematopoietic cells. Biochem J 326:407-413.
6. Eaves CJ and Eaves AC (1992) Fundamental control of hematopoiesis, in Handbook of Experimental Pharmacology (Fisher JW ed) pp 5-31, Springer Verlag, Berlin, Germany.
7. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildovan D, Shooley RT, Jackson GG, Durack DT and King D (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:185-191.
8. Gallicchio VS, Hughes NK and Tse KF (1993) In vivo effect of interleukin 3 and erythropoietin, either alone or in combination, on the hematopoietic toxicity associated with zidovudine. Cytokine 5:62-71.
9. Gallicchio VS and Hughes NK (1992) Influence of interleukin-3 on zidovudine (AZT)-induced in vitro toxicity to human hematopoietic progenitors. Int J Cell Cloning 10:99-104.
10. Gallicchio VS and Hughes NK (1994) Influence of interleukin-3 (IL-3) on the hematopoietic toxicity associated with combination anti-viral drugs (zidovudine and DDI) in vitro using retrovirus-infected bone marrow cells. Int J Immunopharmacol 16:359-366.
11. Ganser A and Hoelzer D (1993) Therapeutic value of interleukin-3 given alone or in combination with other cytokines. Nouvelle Rev Francaise Hematol 35:245-246.
12. Gillio AP, Faulkner LB, Alter BP, Reilly L, Klafter R, Heller G, Young DC, Lipton JM, Moore MA and O'Reilly RJ (1993) Successful treatment of Diamond-Blackfan anemia with interleukin 3. Stem Cells 121(Suppl 2):123-130.
13. Gogu SR, Beckman BS, Wilson RB and Agrawal KC (1995) Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Biochem Pharmacol 50:413-419.
14. Kreuzer KA, Rockstroh JK, Jelkmann W, Theissen A, Spengler U and Sauerbruch T (1997) Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interkeukin-6 and their soluble receptors. Br J Haematol 96:235-239.
15. Lemolai RM, Fortuna A, Fogli M, Gherlizoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC and Tura S (1995) Proliferative response of human bone marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Exp Hematol 23:1520-1526.
16. Mcniece IA and Briddell RA (1994) Primitive hematopoietic colony forming cells with high proliferative potential, in Culture of Hematopoietic Cells (Freshney RI, Pragnell LB and Freshney MG, pp 23-39, Wiley-Liss, New York, NY.
17. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW and Broder S (1985) 3′Azido-3′deoxythymidine BWA509UO: An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus. Proc Natl Acad Sci USA 82:7096-7100.
18. Nand S, Sosman J, Godwin JE and Fisher RI (1994) A phase I/I. I. study of sequential interleukin 3 and granulocyte-macrophage colony stimulating factor in myeolodys-plastic syndromes. Blood 83:357-360.
19. Niederwieser D, Goldschmitt J, Hladik F, Fritz A, Ohler L, Bettelheim P, Huber C and Lechner K (1995) Effect of interleukin-3 pretreatment on granulocyte/ macrophage colony-stimulating factor induced mobilization of circulating haematopoietic progenitor cells. Br J Haematol 91:299-305.
20. Nimer SD, Paquette PL, Ireland P, Resta D, Young D and Golde DW (1994) A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodisplasia. Exp Hematol 22:875-880.
21. Pell JM and Bates PC (1992) Differential actions of growth hormone and insulin-like growth factor-I in tissue protein metabolism in dwarf mice. Endocrinology 130: 1942-1950.
22. Pragnell IB, Freshney MG and Wright EG (1994) CFU-A assay for measurement of murine and human early progenitors, in Culture of Hematopoietic Cells (Freshney RI, Pragnell IB and Freshney MG eds) pp 67-79, Wiley-Liss, New York, NY.
23. Raina N, Cameron RG and Jeejeebhoy KN (1997) Gastrointestinal, hepatic, and metabolic effects of enterai and parenteral nutrition in rats infused with tumor necrosis factor. J Parenteral Enterai Nutr 21:7-13.
24. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch D, Jackson GG, Durack DT and Nusinoff-Lehrman S (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:192-197.
25. Scadden DT, Wang A, Zsebo KM and Groopman JE (1994) In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS 8:193-196.
26. Scadden DT, Levine JD, Bresnahan J, Gere J, Mcgrath J, Wang Z, Resta DJ, Young D and Hammer SM (1995) In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses 11:731-740.
27. Shimon I and Shpilberg O (1995) The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leukemia Res 19: 233-240.
28. Seipelt G, Ganser A, Duranceyk H, Maurer A, Ottmann OG and Hoelzer D (1998) Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 84:749-751.
29. Trinder P (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24-28.
30. Tzarfaty G, Longo DL and Murphy WJ (1994) Human insulin-like growth factor I exerts hematopoietic growth factor-promoting effects after in vivo administration. Exp Hematol 22:1273-1277.
31. Vadhan-Raj S, Broxmeyer HE, Andreff M, Bandres JC, Buescher S, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, Garrison L and Williams DE (1995) In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal erythropoiesis: A phase I study. Blood 86:2098-2105.